Table 4.
Comparisons of laboratory parameters between drug groups at baseline or at the time of critical values.
| Vancomycin (n = 99) | Digoxin (n = 25) | Tacrolimus (n = 35) | P value # | |
|---|---|---|---|---|
| WBC (× 109/L) | ||||
| Baseline | 9.600 (0.7–44.3) | 7.2 (4.2–35.2) | 6.5 (1.3–21.8) | 0.289 |
| Critical value | 8.600 (1.2–38.6) | 11.1 (5.6–22.1) | 8.0 (0.7–19.4) | 0.818 |
| N (%) | ||||
| Baseline | 80.7 (24–97.2) | 79.5 (62–92.4) | 70.2 (28.9–98.4) | 0.082 |
| Critical value | 81.9 (42.6–95.7) | 82.5 (65.7–91.8) | 88.6 (43.5–96.9) | 0.371 |
| L (%) | ||||
| Baseline | 12.50 (1.1–51.9) | 12.2 (1.2–29.8) | 16.6 (0.7–62.6) | 0.033* |
| Critical value | 10.10 (1–41.1) | 10.4 (3.2–22.3) | 8.25 (0.5–2.6) | 0.711 |
| Hb (g/L) | ||||
| Baseline | 106.0 (25–192) | 106.0 (71–204) | 98.0 (45–147) | 0.371 |
| Critical value | 82.0 (47–140) | 79.0 (55–174) | 84.0 (42–135) | 0.207 |
| PLT (× 1012/L) | ||||
| Baseline | 174.0 (23–614) | 170.0 (73–898) | 211.0 (18–526) | 0.579 |
| Critical value | 166.0 (2–565) | 140.0 (47–1120) | 126.0 (12–508) | 0.455 |
| TB (mg/L) | ||||
| Baseline | 14.6 (3.3–405.8) | 17.4 (8.7–91.8) | 13.1 (4.1–373.4) | 0.576 |
| Critical value | 18.6 (11.3–540.6) | 31.3 (9.4–276.8) | 15.5 (4.2–368.2) | 0.894 |
| TP (g/dL) | ||||
| Baseline | 63.15 (26.3–88.6) | 63.30 (48.2–43.7) | 61.1 (40.3–79.9) | 0.932 |
| Critical value | 59.8 (28.9–79.1) | 60.9 (47.6–73.5) | 62.2 (30.3–70.1) | 0.529 |
| ALB (g/dL) | ||||
| Baseline | 32.50 (14–49.7) | 32.70 (24.2–42.9) | 33.35 (22.0–42.8) | 0.795 |
| Critical value | 32.95 (16.4–47.2) | 33.00 (28.1–38.8) | 35.2 (18.6–44.7) | 0.742 |
| ALT (IU/L) | ||||
| Baseline | 29.00 (3–2230) | 22.00 (3–106) | 31.00 (9–1497) | 0.614 |
| Critical value | 34.0 (1–1982) | 26.5 (8–209) | 32.0 (9–595) | 0.609 |
| AST (IU/L) | ||||
| Baseline | 29.00 (5–4480) | 37.00 (8–474) | 36.00 (13–1802) | 0.844 |
| Critical value | 41.0 (9–2280) | 43.0 (19–305) | 38.0 (13–787) | 0.748 |
| BUN | ||||
| Baseline | 6.820 (1.3–59.6) | 10.82 (4.3–33.1) | 8.2 (1.3–17.7) | 0.072 |
| Critical value | 8.54 (1.4–36.9) | 18.22 (7.6–35.3) | 10.65 (2.7–34.1) | 0.002 |
| Cr | ||||
| Baseline | 75.00 (10–1476) | 161.0 (38–850) | 84.5 (15–780) | 0.446 |
| Critical value | 81.5 (5–805) | 161.5 (75–785) | 87.5 (12–540) | 0.007 |
| CRP | ||||
| Baseline | 48.76 (0.7–314.6) | 14.6 (4–252.1) | 11.5 (1.6–208.) | 0.144 |
| Critical value | 55.65 (4.4–293.3) | 47.0 (5.5–126) | 49.50 (5.3–34.9) | 0.256 |
| PCT | ||||
| Baseline | 0.5 (0–88.2) | 0.4 (0.1–58.0) | 0.2 (0–78.4) | 0.993 |
| Critical value | 1.450 (0.1–93.1) | 2.97 (0.2–19.4) | 1.170 (0.1–75.2) | 0.856 |
| NTproBNP | ||||
| Baseline | 1477 (32–20,518) | 12,577 (466–35,000) | 1923 (15–17,022) | < 0.001* |
| Critical value | 2104 (27–50,852) | 11,824 (4927–35,000) | 3780 (206–34,475) | 0.005* |
WBC, white blood cell; Hb, hemoglobin; PLT, platelet; N, neutrophil; L, lymphocyte; TB, total bilirubin; TP, total protein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; CRP, C-reactive protein; PCT, procalcitonin; NTproBNP, N-terminal pro B-type Natriuretic Peptide. #P values were derived from comparison of multiple drug groups using one-way ANOVA analysis. *P < 0.05 considered statistically significant.